Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide. Focused on cost and process efficiencies, we deliver innovative technologies and solutions that help set new standards in bioprocessing.
Repligen is a bioprocessing-focused life sciences company bringing over 30 years of expertise and innovation to our customers. We are inspiring advances in bioprocessing through the development and commercialization of high-value products and flexible solutions that address critical steps in the production of biologic drugs, principally monoclonal antibodies.
Our core Protein A affinity ligands business is complemented by an expanding suite of technology-leading bioprocessing products that we sell direct to biopharmaceutical companies and contract manufacturers worldwide. All of our bioprocessing products are meaningfully differentiated from alternatives to the benefit of our customers. Our Protein A ligands are used to purify over 50 monoclonal antibody-based drugs on the market and more than 300 in clinical development. Our XCell™ ATF cell concentration device, and LONG® cell culture supplements are at the forefront of innovation in bioprocessing. To provide customers with the broadest selection of OPUS® pre-packed chromatography columns from bench-scale to production-scale, Repligen acquired Atoll GmBH of Weingarten, Germany, solidifying Repligen as a leading supplier in this fast-growing segment.
Our business is influenced by the growth in demand for biologic drugs, particularly the global market for monoclonal antibodies (mAbs). Demand for our products is associated with the overall volume of mAbs manufactured; there is little connection to final drug pricing or the clinical or commercial success or failure of an individual biologic drug.
As the number of biologic drugs on the market and in development continues to increase, and as worldwide access to biologics expands with the emergence of biosimilar and bio-better versions of original drugs, biopharmaceutical manufacturers are tasked with reducing the time and cost associated with production while improving yield and retaining the highest levels of product quality.
These market dynamics are driving process intensification and adoption of disposable technologies and other products that offer convenience, flexibility and the ability to improve capacity utilization in the most modern continuous processing facilities as well as in standard batch processing facilities. The bioprocessing products manufactured by Repligen are designed to address these important needs of biopharmaceutical manufacturers in an increasingly competitive environment.
Repligen is a trusted and forward-thinking partner in the production of biologics that improve human health worldwide, committed to supporting our customers with superior technology, service and applications expertise. We are executing on a focused growth strategy that involves ongoing innovation and collaboration, targeted acquisitions and commercial expansion.
Our manufacturing facilities are located at our Waltham, MA headquarters in the U.S., in Lund, Sweden and in Weingarten, Germany. We market our products globally through a direct commercial organization in the U.S., Europe and Asia, as well as through strategic partners in select markets.